Table 6.
Disease Severity
| Mild (n=452) | Moderate (n=188) | Severe (n=232) | P value | |
|---|---|---|---|---|
| Sex | 0.03 | |||
| Male | 245 (54.2%) | 98 (52.1%) | 101 (43.5%) | |
| Female | 207 (45.8%) | 90 (47.9%) | 131 (56.5%) |
| N=436 | N=180 | N=222 | ||
|---|---|---|---|---|
| Age at diagnosis, y, median (interquartile range) | 9 (7–12) | 10 (8–12) | 10 (7–13) | 0.11 |
| Race | <0.001 | |||
| American Indian or Alaska Native | 17 (3.8%) | 14 (7.4%) | 8 (3.4%) | |
| Asian | 14 (3.1%) | 9 (4.8%) | 17 (7.3%) | |
| Black | 58 (12.8%) | 37 (19.7%) | 61 (26.3%) | |
| Native Hawaiian or other Pacific Islander | 30 (6.6%) | 11 (5.9%) | 24 (10.3%) | |
| White | 235 (52.0%) | 80 (42.6%) | 71 (30.6%) | |
| Other | 64 (14.2%) | 23 (5.1%) | 39 (16.8%) | |
| Unknown | 34 (7.5%) | 14 (7.4%) | 12 (5.2%) | |
| Ethnicity | 0.79 | |||
| Hispanic or Latino | 73 (16.2%) | 29 (15.4%) | 42 (18.1%) | |
| Non‐Hispanic or Latino | 339 (75.0%) | 139 (73.9%) | 172 (74.1%) | |
| Unknown | 40 (8.8%) | 20 (10.6%) | 18 (7.8%) | |
| Primary language | 0.001 | |||
| English | 392 (86.7%) | 155 (82.4%) | 183 (78.9%) | |
| Spanish | 36 (8.0%) | 20 (10.6%) | 18 (7.8%) | |
| Other | 17 (3.8%) | 13 (6.9%) | 28 (12.1%) | |
| Unknown | 7 (1.5%) | 0 (0%) | 3 (1.3%) |
| N=436 | N=176 | N=226 | ||
|---|---|---|---|---|
| Has health insurance | 407 (90.0%) | 165 (87.8%) | 206 (88.8%) | 0.51 |
| N=399 | N=170 | N=222 | ||
|---|---|---|---|---|
| Type of health insurance | 0.64 | |||
| Private | 167 (36.9%) | 69 (36.7%) | 79 (34.1%) | |
| Medicaid or Medicare | 201 (44.5%) | 90 (47.9%) | 123 (53.0%) | |
| Both | 2 (0.4%) | 0 (0%) | 0 (0%) | |
| Unknown | 37 (8.2%) | 6 (3.2%) | 4 (1.7%) | |
| Diagnosed in the United States | 0.09 | |||
| Yes | 381 (84.3%) | 164 (87.2%) | 186 (80.2%) | |
| No | 54 (11.9%) | 18 (9.6%) | 38 (16.4%) | |
| Unknown | 17 (3.8%) | 6 (3.2%) | 8 (3.4%) |
| N=354 | N=161 | N=182 | ||
|---|---|---|---|---|
| Parent primary language English | 297 (65.7%) | 133 (70.7%) | 137 (59.1%) | 0.047 |
| Travel exposure before diagnosis | 0.02 | |||
| Yes | 65 (14.4%) | 29 (15.4%) | 53 (22.8%) | |
| No | 68 (15.0%) | 32 (17.0%) | 45 (19.4%) | |
| Unknown | 319 (70.6%) | 127 (67.6%) | 134 (57.8%) | |
| Travel to endemic region | 49 (10.8%) | 25 (13.3%) | 45 (19.4%) | 0.31 |
| Prescribed secondary prophylaxis |
0.43 |
|||
| Yes | 437 (96.7%) | 181 (96.3%) | 224 (96.6%) | |
| No | 9 (2.0%) | 7 (3.7%) | 5 (2.2%) | |
| Unknown | 6 (1.3%) | 0 (0%) | 3 (1.2%) |
| N=430 | N=180 | N=221 | ||
|---|---|---|---|---|
| Initial antibiotic choice for secondary prophylaxis | 0.09 | |||
| BPG, intramuscular | 231 (53.7%) | 118 (65.5%) | 142 (64.2%) | |
| Oral penicillin | 172 (40.0%) | 52 (28.9%) | 67 (30.3%) | |
| Macrolid | 10 (2.3%) | 6 (3.3%) | 7 (3.2%) | |
| Sulfadiazine | 5 (1.2%) | 1 (0.6%) | 2 (0.9%) | |
| Other | 12 (2.8%) | 3 (1.7%) | 3 (1.4%) |
| N=80 | N=27 | N=32 | ||
|---|---|---|---|---|
| Reason for not using BPG | 0.130 | |||
| Patient/family preference | 62 (77.5%) | 20 (74.1%) | 22 (68.8%) | |
| Patient allergy | 16 (20%) | 4 (14.8%) | 10 (31.2%) | |
| Other | 2 (2.5%) | 3 (11.1%) | 0 (0%) |
n (%) unless otherwise indicated. BPG indicates benzathine penicillin G.